-
Hyderabad: Covid has tested and proved the credibility of the Indian pharma industry as one of the core sectors for the nation. The industry rose to the occasion by ramping up research and manufacturing to find solutions for the treatment. Pharma companies are optimistic that normalcy will return in the next one year. Speaking at […]
-
Hyderabad: Indian pharma industry is going through a lot of transformation and achieving scale. While export opportunities keep increasing, there is equal attention on strengthening the drug pipeline driven by research investments. Speaking at the CEO Conclave at BioAsia on Friday, Ajay Piramal, chairman, Piramal Group said, the company is increasing its investments onto more […]
-
Hyderabad: India is labelled as the preeminent pharmacy of the world, but the nation also should be known as the innovator of the world. When you want to create value, it starts with a patent and IP culture should be incentivised, and that’s why India should create a patent box regime, point out experts. A […]
-
New Delhi: Registration process for adolescents’ vaccination on Cowin App will begin from January 1, Cowin Platform Chief Dr RS Sharma said on Monday. Eligible teens can register themselves on the Cowin app through their Aadhar Card and school IDs. The registration process will begin from January 1 for teens using their Aadhar Card. He […]
-
MoHFW may approve Covid vaccine this month for those aged between 12 years and 18 years
-
Nod for Zydus Cadila'd Covid vaccine for children will help India ramp up its vaccination programme quickly
-
The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
-
Zydus Cadila said HER2 positive breast cancer is considered an aggressive form and constitutes 20 to 25 per cent of all breast cancers.
-
Task Force also discussed with them various alternatives to drugs that are in high demand like Remdesivir
-
Zydus has received restricted emergency use approval from DCGI for the use of 'Virafin', PegIFN in treating moderate COVID-19 infection in adults
-
This government's approval for use of the antiviral drug comes at a time when India's daily COVID tally is crossing the 3-lakh mark.
-
Phase-III clinical trials with Pegylated Interferon Alpha 2b, which the company sells under the brand name 'PegiHep' have shown promising results in treating COVID-19, Zydus Cadila said
-
New Delhi: Drug firm Zydus Cadila has received final approval from the US health regulator to market Liothyronine Sodium tablets that are used to treat underactive thyroid. Liothyronine is a man-made form of thyroid hormone which is used to treat an underactive thyroid (hypothyroidism). It replaces or provides more thyroid hormone, which is normally made […]
-
The Nation's first indigenously developed DNA vaccine candidate against COVID-19, ZyCoV-D, by M/s Zydus Cadila has been approved by Drugs Controller General of India (DCGI), for the conduct of the Phase III clinical trials
-
It also said that protective level of antibodies generally develop two weeks after receiving the second dose.
-
The trials, which will commence in December, will be conducted on 250 patients across 20-25 centres in India.
-
Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D is over and it has commenced phase-II clinical trials from August.
-
Modi began his three-city visit on Saturday to review coronavirus vaccine development work by going to pharma major Zydus Cadila's manufacturing facility near Ahmedabad in the morning.
-
Zydus Cadila has announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
-
Zydus Cadila had announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
